NCT00445939View on ClinicalTrials.gov

A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

90

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

December 31, 2007

Conditions

Crohn's Disease

Interventions

BIOLOGICAL

adalimumab

160 mg at Week 0, 80 mg at Week 2

BIOLOGICAL

adalimumab

80 mg at Week 0, 40 mg at Week 2

BIOLOGICAL

placebo

Placebo at Week 0 and Week 2

Trial Locations (18)

Unknown

Aichi

Chiba

Ehime

Fukuoka

Hiroshima

Hokkaido

Hyōgo

Kagawa

Kanagawa

Kochi

Kyoto

Miyagi

Okayama

Okinawa

Osaka

Shiga

Shizuoka

Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Abbott Japan Co.,Ltd

INDUSTRY

collaborator

Eisai Co., Ltd.

INDUSTRY

lead

Abbott

INDUSTRY